Two Phase 3 clinical trials testing Tyvaso (treprostinil) in people with idiopathic pulmonary fibrosis (IPF) both met their ...

Columnist Ann Reynoso says she can't get used to the chronic cough of PF, but she's working to overcome the fear and ...

As he navigates his rare disease journey, columnist Samuel Kirton feels it is his responsibility to be a "five-star patient." ...

Brainomix and Boehringer Ingelheim will advance testing of an AI-based analysis tool that may enable earlier diagnosis of PF.

Insilico Medicine will soon launch an early clinical trial in China to test an inhaled version of its therapy candidate rentosertib in healthy volunteers and people with idiopathic pulmonary fibrosis ...

Enrollment has finished ahead of schedule in a Phase 2 clinical trial testing Calluna Pharma‘s experimental antibody therapy CAL101 in people with idiopathic pulmonary fibrosis (IPF). The Phase 2 ...

The U.S. Food and Drug Administration (FDA) has approved a generic version of Ofev (nintedanib) for easing lung scarring in people with idiopathic pulmonary fibrosis (IPF). The new generic nintedanib ...

In 2019 Christie Patient relocated to San Francisco to care for her mother, Holly, before and after her double-lung transplant. Holly’s idiopathic pulmonary fibrosis diagnosis came only months before ...

Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...

The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung ...

Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving ...